UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 0-20580

 

PATHFINDER CELL THERAPY, INC.

(Exact name of registrant as specified in its charter)

 

12 Bow Street, Cambridge, Massachusetts 02138

(617) 245-0289

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock

(Title of each class of securities covered by this Form)

 

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

  Rule 12g-4(a)(1) ☐ 
  Rule 12g-4(a)(2) ☒ 
  Rule 12h-3(b)(1)(i) ☐ 
  Rule 12h-3(b)(1)(ii) ☒ 
  Rule 15d-6 ☐ 

 

Approximate number of holders of record as of the certification or notice date: 316

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Pathfinder Cell Therapy, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: March 30, 2016 By: /s/ John Benson
    John Benson
    Chief Financial Officer

 

 

 

 

Pathfinder Cell Therapy (CE) (USOTC:PFND)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Pathfinder Cell Therapy (CE) 차트를 더 보려면 여기를 클릭.
Pathfinder Cell Therapy (CE) (USOTC:PFND)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Pathfinder Cell Therapy (CE) 차트를 더 보려면 여기를 클릭.